XML 20 R18.htm IDEA: XBRL DOCUMENT

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2013
Subsequent Events [Abstract]
Subsequent Events	(13) Subsequent Events During the third quarter through August 5, 2013, the Company sold approximately 4.6 million shares of its common stock under the March 2013 Sales Agreement through an “at the market” equity offering program for net proceeds of approximately $1.8 million. The shares were issued pursuant to an effective registration statement on Form S-3 (333-187230). The net proceeds will be used for general corporate purposes, including, but not limited to, funding of the Company’s clinical trials, commercialization of our products, obtaining regulatory approvals, capital expenditures and working capital. As of August 5, 2013, the Company has approximately $48.2 million remaining under the program. As a result of the sales made under the program, the exercise price of all warrants outstanding has been reduced to $0.37. The Company completed an evaluation of the impact of any subsequent events through the date financial statements were issued and determined there were no other subsequent events requiring disclosure in or adjustment to these financial statements.